Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by metaanalysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
Abstract
Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by metaanalysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
참고문헌 (46)
- Assy N, "Fatty infiltration of liver in hyperlipidemic patients", Dig Dis Sci, 45, pp.1929~1934 (2000)
- Van Rooyen DM, "Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome", J Hepatol, 59, pp.144~152 (2013)
- Athyros VG, "Statins and nonalcoholic fatty liver disease: a bright future?", Expert Opin Investig Drugs, 22, pp.1089~1093 (2013)
- Nelson A, "A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis : a randomized placebo-controlled trial", J Clin Gastroenterol, 43, pp.990~994 (2009)
- Foster T, "Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease : the St Francis Heart Study randomized clinical trial", Am J Gastroenterol, 106, pp.71~77 (2011)
- Park H, "Efficacy of longterm ezetimibe therapy in patients with nonalcoholic fatty liver disease", J Gastroenterol, 46, pp.101~107 (2011)
- Eslami L, "Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis", Cochrane Database Syst Rev, (12), pp.CD008623~ (2013)
- Loomba R, "Ezetimibe for the treatment of nonalcoholic steatohepatitis : assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial(MOZART trial)", Hepatology, 61, pp.1239~1250 (2015)
- Takeshita Y, "The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism : a randomised controlled trial", Diabetologia, 57, pp.878~890 (2014)
- Huang X, "Evaluation of PICO as a knowledge representation for clinical questions", AMIA Annu Symp Proc, 2006, pp.359~363 (2006)
- Lee SS, "Radiologic evaluation of nonalcoholic fatty liver disease", World J Gastroenterol, 20, pp.7392~7402 (2014)
- Ma X, "Imaging-based quantification of hepatic fat : methods and clinical applications", Radiographics, 29, pp.1253~1277 (2009)
- Lo CK, "Newcastle-Ottawa scale : comparing reviewers’ to authors’ assessments", BMC Med Res Methodol, 14, pp.45~ (2014)
- Brunt EM, "Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Abel T, "Safety and efficacy of combined ezetimibe", simvastatin treatment and simvastatin monotherapy in patients with nonalcoholic fatty liver disease, 2009, pp.15, MS6~MS11
- Abel T, "Efficacy and safety of ezetimibe", simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease, 2009, pp.150, 989~993
- Aggarwal V, "Statins and liver injury in morbidly obese subjects with nonalcoholic fatty liver disease", Hepatology, 50, pp.789~ (2009)[DOI]
- Ahmed MH, "Ezetimibe and recent clinical trials : a look on the bright side", Expert Opin Drug Saf, 9, pp.511~514 (2010)
- Arendt BM, "Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?", Am J Gastroenterol, 106, pp.78~80 (2011)
- Blais P, "Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia", Dig Dis Sci, 61, pp.1714~1720 (2016)
- Bril F, "Safety of statin therapy in patients with prediabetes or T2DM and NASH: a longterm prospective study", Diabetes, 62(Suppl 1), pp.A164~ (2013)
- Carnelutti A, "Effect of statin therapy vs diet in hypercholesterolemic patients affected by nonalcoholic steatohepatitis (NASH)", Dig Liver Dis, 44(Suppl 1), pp.S25~S26 (2012)
- Chan DC, "Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet", Diabetes Care, 33, pp.1134~1139 (2010)
- De Keyser CE, "Association between statin therapy and non-alcoholic fatty liver disease in a large population-based study", Pharmacoepidemiol Drug Saf, 22, pp.373~ (2013)
- Drapkina OM, "Treatment of non-alcoholic fatty liver disease and dyslipidemia in patients with metabolic syndrome using simvastatin and ursodeoxycholic acid", Diab Vasc Dis Res, 8, pp.56~57 (2011)
- Drapkina OM, "Ademetionine and simvastatin in patients with nonalcoholic fatty liver disease and metabolic syndrome", Endocr Pract, 17, pp.21~ (2011)[DOI]
- Ekstedt M, "Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes : a histopathological follow-up study", J Hepatol, 47, pp.135~141 (2007)
- Elsheikh E, "Angiogenic growth factors associated with statins use in patients with nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD)", Gastroenterology, 146(5 Suppl 1), pp.S710~ (2014)
- Georgescu EF, "Therapeutic options in non-alcoholic steatohepatitis(NASH) : are all agents alike? Results of a preliminary study", J Gastrointestin Liver Dis, 16, pp.39~46 (2007)
- Kargiotis K, "Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia : a preliminary report", Curr Vasc Pharmacol, 12, pp.505~511 (2014)
- Kiyici M, "Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis", Can J Gastroenterol, 17, pp.713~718 (2003)
- Koehler EM, "Association between statin use and nonalcoholic fatty liver disease in a population-based study", Hepatology, 1(56 Suppl 1), pp.595A~596A (2012)
- Maroni L, "Achievement of lipid targets in non alcoholic fatty liver disease during statin treatment", J Hypertens, 28(Suppl A), pp.e547~ (2010)
- Maroni L, "Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease", Am J Med Sci, 342, pp.383~387 (2011)
- Mihaila RG, "Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis", Hepatogastroenterology, 56, pp.1117~1121 (2009)
- Oni E, "Statin use is not associated with presence of and severity of non-alcoholic fatty liver disease", J Am Coll Cardiol, 61(10 Suppl S), pp.E1427~ (2013)
- Patel A, "Management strategies used for nonalcoholic fatty liver disease : survey of AASLD members", Gastroenterology, 136, pp.A847~ (2009)
- Pireau L, "Does ezetimibe could correct hepatic steatosis?", Acta Clin Belg, 68, pp.463~ (2013)
- Reihner E, "Effect of pravastatin on hepatic cholesterol metabolism", Fortschr Med, 109, pp.189~194 (1991)
- Riley P, "Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease : a retrospective study", Int J Clin Pract, 62, pp.374~381 (2008)
- Samy W, "Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin", Arab J Gastroenterol, 12, pp.80~85 (2011)
- Skrypnyk IM, "Optimization of longterm treatment with rosuvastatin of patients with myocardial infarction in combination with non-alcoholic steatohepatitis", Lik Sprava, (5-6), pp.113~121 (2014)
- Zvenigorodskaja L, "Evaluation of effectiveness in the hypolipidemic therapy of patients with atherogenic dislipoproteinemia and nonalcoholic fatty liver disease", Am J Hypertens, 22(Suppl 1), pp.10~ (2009)
- Permutt Z, "Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease : MRI accurately quantifies hepatic steatosis in NAFLD", Aliment Pharmacol Ther, 36, pp.22~29 (2012)
- Sattar N, "Statins and risk of incident diabetes : a collaborative meta-analysis of randomised statin trials", Lancet, 375, pp.735~742 (2010)